About Ascendis pharma a/s
Ascendis Pharma A/S: Revolutionizing Biopharmaceuticals with TransCon Technology
Ascendis Pharma A/S is a Danish biopharmaceutical company that specializes in developing innovative therapies for rare diseases. The company was founded in 2007 by a team of experienced industry professionals who shared a common vision of improving the lives of patients suffering from debilitating conditions.
At Ascendis, we are committed to making a meaningful difference for patients, caregivers, and healthcare providers (HCPs) worldwide. We achieve this by applying our proprietary TransCon technology platform to build a leading, fully integrated biopharma company.
Our TransCon technology platform is based on prodrug technology that enables the sustained release and targeted delivery of therapeutic proteins. This approach allows us to optimize the pharmacokinetic profile of our drugs, resulting in improved efficacy and safety profiles compared to traditional formulations.
We have leveraged our TransCon technology platform to develop a pipeline of novel therapies for rare endocrine diseases such as hypoparathyroidism, growth hormone deficiency (GHD), and acromegaly. Our lead product candidate is TransCon hGH (lonapegsomatropin), an investigational long-acting prodrug of human growth hormone (hGH) currently being evaluated in phase 3 clinical trials for pediatric GHD.
In addition to our lead program, we have several other promising candidates in various stages of development. These include:
-TransCon PTH: An investigational long-acting prodrug of parathyroid hormone (PTH) being developed for the treatment of hypoparathyroidism.
-TransCon CNP: An investigational long-acting prodrug of C-type natriuretic peptide (CNP) being developed for achondroplasia.
-TransCon GH: An investigational long-acting prodrug that combines lonapegsomatropin with an optimized dose titration algorithm designed to improve treatment outcomes in adult GHD.
At Ascendis Pharma A/S, we are dedicated to advancing science and improving patient outcomes through innovation and collaboration. We work closely with patient advocacy groups, academic institutions, regulatory agencies, and other stakeholders across the healthcare ecosystem to ensure that our products meet the highest standards of safety and efficacy.
Our commitment extends beyond drug development; we also strive to make a positive impact on society through corporate social responsibility initiatives focused on environmental sustainability, diversity & inclusion, employee well-being & engagement as well as community outreach programs aimed at supporting underserved populations around the world.
In conclusion,
Ascendis Pharma A/S is revolutionizing biopharmaceuticals with its proprietary Transcon technology platform which enables sustained release & targeted delivery resulting in improved efficacy & safety profiles compared traditional formulations. With its pipeline consisting mainly rare endocrine disease treatments like hypoparathyroidism or acromegaly among others; it's no wonder why they're quickly becoming one most sought-after companies within their field!